Cytokinetics, Incorporated (CYTK)
NASDAQ: CYTK · Real-Time Price · USD
49.44
-1.69 (-3.31%)
At close: Sep 15, 2025, 4:00 PM EDT
49.66
+0.22 (0.44%)
After-hours: Sep 15, 2025, 5:50 PM EDT
Cytokinetics Revenue
Cytokinetics had revenue of $66.77M in the quarter ending June 30, 2025, with 26,714.86% growth. This brings the company's revenue in the last twelve months to $85.74M, up 2,635.74% year-over-year. In the year 2024, Cytokinetics had annual revenue of $18.47M with 145.34% growth.
Revenue (ttm)
$85.74M
Revenue Growth
+2,635.74%
P/S Ratio
68.31
Revenue / Employee
$172,165
Employees
498
Market Cap
5.92B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 18.47M | 10.94M | 145.34% |
Dec 31, 2023 | 7.53M | -87.06M | -92.04% |
Dec 31, 2022 | 94.59M | 24.16M | 34.30% |
Dec 31, 2021 | 70.43M | 14.60M | 26.15% |
Dec 31, 2020 | 55.83M | 28.96M | 107.79% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
CYTK News
- 6 days ago - Cytokinetics, Incorporated (CYTK) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript) - Seeking Alpha
- 13 days ago - Cytokinetics, Incorporated (CYTK) Presents At Citi's Biopharma Back To School Conference Transcript - Seeking Alpha
- 13 days ago - Cytokinetics: Game-Changing Data Confirms Best-In-Class Potential - Seeking Alpha
- 13 days ago - Cytokinetics, Incorporated - Exploring The Changing Treatment Paradigm Transcript - Seeking Alpha
- 13 days ago - Cytokinetics Stock Jumps. The Biotech's Heart Drug Wows. - Barrons
- 15 days ago - Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025 - GlobeNewsWire
- 16 days ago - Cytokinetics' drug more effective for heart disease symptoms than standard-of-care - Reuters
- 16 days ago - Cytokinetics Announces Primary Results from MAPLE-HCM Presented at the European Society of Cardiology Congress 2025 and Published in The New England Journal Of Medicine - GlobeNewsWire